StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Tukysa (tucatinib by Quarter

Tukysa (tucatinib — HER2+ breast/colorectal cancer, via Seagen) — U.S. reported YoY (%) (%)

Pfizer Tukysa (tucatinib: -11.0% in Q2 2026, down 22.0 pts from a year earlier.

Latest, Q2 2026
-11.0%
Period ended Jun 28, 2026
Change on a year earlier
-22.0 pts
11.0% in Q2 2025
History
6 quarters
Since Q1 2025
Sources
6
Documents cited below

Where the Q2 2026 figure comes from

“|| Tukysa | 138 | 132 | 5% | 4% | 96 | 107 | (11%) | 42 | 24 | 73% | 67%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗

Reported in Form 8-K Revenue Tables.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Pfizer Tukysa (tucatinib (%), quarterly Q1 2025–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/tukysa-yoy-us

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.